• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Anebulo Pharmaceuticals Inc (NQ: ANEB )

    2.900 UNCHANGED
    Streaming Delayed Price Updated: 3:19 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 2.900
    Bid (Size) 2.660 (1)
    Ask (Size) 3.550 (19)
    Prev. Close 2.900
    Today's Range 2.900 - 2.900
    52wk Range 1.620 - 4.050
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
    Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The... 
    Via Benzinga
    Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +17.37%
    +17.37%
    1 Month
    +0.35%
    +0.35%
    3 Month
    +15.54%
    +15.54%
    6 Month
    +31.82%
    +31.82%
    1 Year
    +16.00%
    +16.00%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
    Via Benzinga
    Anebulo Pharmaceuticals: Q3 Earnings Insights
    Via Benzinga
    Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Anebulo Pharmaceuticals Announces New CEO
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication
    Via Benzinga
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Antidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid Intoxication
    Via Benzinga
    Latest Executive Changes In Marijuana Industry, New Appointments & Resignations
    Via Benzinga
    Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Acute Cannabinoid Intoxication: This Pharma Company's Clinical Trials To Reduce And Treat Symptoms
    Via Benzinga
    Why Heart Test Laboratories Are Trading Higher By 136%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.